* CytoTherapeutics Inc., of Providence, R.I., withdrew its proposedfollow-on public offering of 2 million shares, citing poor marketconditions and the company's cash reserves of about $19 million.CytoTherapeutics said it is pursuing alternate financing.

* Gensia Inc., of San Diego, received a product license in Sweden tomarket its GenESA system for diagnosing coronary artery disease inassociation with electrocardiography, echocardiography andradionuclide imaging.

* Martek Biosciences Corp., of Columbia, Md., said it plans to pay$10 million in cash, stock and promissory notes to purchase afermentation facility from Golden Technologies Co. Inc. inWinchester, Ky. The deal is expected to be finalized in March.

* Matritech Inc., of Cambridge, Mass., received a Small BusinessInnovative Research grant from the National Cancer Institute for$88,000. The funds will be used for cloning the gene that expressesPC-1, which has been identified as a prostate cancer-specific nuclearmatrix protein.

* SangStat Medical Corp., of Menlo Park, Calif., began volumemanufacturing of its Transtat product as part of a licensing agreementwith Paris-based Diagnostica Stago S.A. Stago is using Transtat in adiagnostic to test D-Dimer, which is associated with bloodcoagulation disorders. SangStat is developing Transtat for post-transplant monitoring.

* Cypros Pharmaceutical Corp., of Carlsbad, Calif., said a Phase Itrial of CPC-211 for cerebral ischemic disorders showed the drug waswell tolerated at three dose levels. Thirty-six healthy volunteersparticipated in the study.

* NaPro BioTherapeutics Inc., of Boulder, Colo., received approvalfrom Australia's Therapeutic Goods Administration to market itsanti-cancer paclitaxel drug, Anzatax, for advanced refractory ovarianand breast cancers. Anzatax will be sold in Australia by NaPro'spartner, F.H. Faulding & Co. Ltd. in South Australia.

* Pharmos Corp., of New York, said its stock (PARS) will be listedon the Nasdaq SmallCap Market, following a decision by the NasdaqListing Qualifications Committee to remove the company from theNasdaq National Market. The move was effective Jan. 27.

* Synsorb Biotech Inc., of Calgary, Alberta, signed an agreementwith the Alberta Heritage Foundation for Medical Research for$387,000 to help fund Synsorb's Phase II/III of Synsorb Pk fortreatment of Hemolytic Uremic Syndrome, also known as hamburgerdisease.

* VIMRx Pharmaceuticals Inc., of Stamford, Conn., purchasedexclusive rights to technology for synthetic nucleic acid-basedcompounds that target messenger RNA, preventing it from producingdisease-causing proteins. VIMRx declined to disclose financialdetails and did not identify the company selling the technology.

* Zonagen Inc., of The Woodlands, Texas, said Pharmaco LSR Inc.,a clinical research organization in Austin, Texas, will conductZonagen's Phase II trials of oral phentolamine for male impotency atmultiple sites in Germany with 160 patients.

(c) 1997 American Health Consultants. All rights reserved.